Incretin & metabolic research compounds
Eloralintide
Also known as LY3841136 · eloralinitide · amylin agonist
An investigational, selective, long-acting amylin-receptor agonist from Eli Lilly, studied for obesity.
In 60 seconds
Phase 1 proof of concept and a 48-week phase 2 placebo-controlled trial (Lancet, 2025) published; phase 3 and combination studies with tirzepatide under way. Trials report the gastrointestinal profile expected of the amylin class; the phase 2 report describes tolerability across doses.
- Describes eloralintide’s discovery and pharmacology through to clinical proof of concept.
- A phase 1 study characterised pharmacokinetics, tolerability and early body-weight effects.
- Mean body-weight reductions of 9.5% to 20.1% across doses versus 0.4% with placebo over 48 weeks.
Mechanism
Amylin is a pancreatic hormone co-secreted with insulin that acts on hindbrain satiety circuits and slows gastric emptying. Eloralintide was engineered as a selective amylin-receptor agonist with a long half-life, suited to once-weekly dosing in trials.
Research status
Phase 1 proof of concept and a 48-week phase 2 placebo-controlled trial (Lancet, 2025) published; phase 3 and combination studies with tirzepatide under way. Not approved anywhere.
Key studies
Describes eloralintide’s discovery and pharmacology through to clinical proof of concept.
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept — Mol Metab, 2025 · PMID 41109426
A phase 1 study characterised pharmacokinetics, tolerability and early body-weight effects.
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept — Diabetes Obes Metab, 2026 · PMID 41559929
Mean body-weight reductions of 9.5% to 20.1% across doses versus 0.4% with placebo over 48 weeks.
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial — Lancet, 2025 · PMID 41207310
Reviews experimental and early-phase clinical data across amylin analogues.
Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials — Diabetes Obes Metab, 2026 · PMID 42452898
Safety signals in the literature
Trials report the gastrointestinal profile expected of the amylin class; the phase 2 report describes tolerability across doses.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Now in the catalogue
Eloralintide is now in our catalogue as a research vial. Pre-orders are 10% off until the 15 October delivery lands.
Comparisons
Questions
What is Eloralintide?
An investigational, selective, long-acting amylin-receptor agonist from Eli Lilly, studied for obesity. Amylin is a pancreatic hormone co-secreted with insulin that acts on hindbrain satiety circuits and slows gastric emptying. Eloralintide was engineered as a selective amylin-receptor agonist with a long half-life, suited to once-weekly dosing in trials.
What is the research status of Eloralintide?
Phase 1 proof of concept and a 48-week phase 2 placebo-controlled trial (Lancet, 2025) published; phase 3 and combination studies with tirzepatide under way. Not approved anywhere.
What safety signals are reported for Eloralintide?
Trials report the gastrointestinal profile expected of the amylin class; the phase 2 report describes tolerability across doses.
Does Living Water Labs stock Eloralintide?
Not at present. Eloralintide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
